Sector Update: Health Care
3:51PM ET 4/11/2022 MT NewswiresHealth care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.6% while the SPDR Health Care Select Sector ETF (XLV) was...
Quotes Snapshot > MTNB
Matinas BioPharma Holdings Inc MTNB:NYSE American
Last Price$0.79AMEX Closing Price as of 8:00PM ET 6/30/22
Today's Change-0.02(2.46%)
Bid (Size)$0.77 (7)
Ask (Size)$0.82 (7)
Day Low / High$0.77 - 0.82
Volume284.4 K
Read more news Recent News
Sector Update: Health Care Stocks Decline Premarket Monday
9:17AM ET 4/11/2022 MT NewswiresHealth care stocks were declining premarket Monday. The Health Care SPDR (XLV) was down 0.22% and the iShares NASDAQ Biotechnology Index (IBB) was recently...
BioNTech, Matinas BioPharma Sign Exclusive Research Deal on Lipid Nanocrystal Technology
7:21AM ET 4/11/2022 MT NewswiresBioNTech SE (BNTX) and Matinas BioPharma Holdings, Inc. (MTNB) said Monday that they have signed an exclusive research agreement to evaluate the...
Matinas BioPharma Holdings Posts Flat Q4 Net Loss
6:55AM ET 3/08/2022 MT NewswiresMatinas BioPharma Holdings (MTNB) reported a Q4 net loss Tuesday of $0.03 per diluted share, unchanged from a year earlier. Analysts polled by Capital IQ...
View all Commentary and Analysis
Matinas BioPharma (MTNB) Investor Presentation - Slideshow
2:27PM ET 6/11/2022 Seeking AlphaMatinas BioPharma (MTNB) CEO, Jerome Jabbour on Q1 2022 Results - Earnings Call Transcript
12:10PM ET 5/12/2022 Seeking AlphaMatinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour On Q4 2021 Results - Earnings Call Transcript
11:13AM ET 3/08/2022 Seeking AlphaMatinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q3 2021 Results - Earnings Call Transcript
12:48PM ET 11/08/2021 Seeking AlphaCompany Profile
Business DescriptionMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ. View company web site for more details
| Address | 1545 Route 206 South Bedminster, New Jersey 07921-9999 |
| Phone | +1.908.484.8805 |
| Number of Employees | 15 |
| Recent SEC Filing | 05/12/2022 8-K |
| President, Chief Executive Officer & Director | Jerome D. Jabbour |
| Chief Financial Officer | Keith A. Kucinski |
| Chief Scientific Officer & Senior Vice President | Raphael J. Mannino |
| Chief Medical Officer | James J. Ferguson |
Company Highlights
| Price Open | $0.81 |
| Previous Close | $0.81 |
| 52 Week Range | $0.49 - 1.61 |
| Market Capitalization | $171.3 M |
| Shares Outstanding | 216.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/09/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.11 |
| Beta vs. S&P 500 | N/A |
| Revenue | $119.8 K |
| Net Profit Margin | N/A |
| Return on Equity | -43.93% |
Analyst Ratings as of 10/13/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |